

6-2007

The synthesis and evaluation of a more highly conjugated molecular transporter

Aaron M. Almeida

Union College - Schenectady, NY

Follow this and additional works at: <https://digitalworks.union.edu/theses>



Part of the [Chemistry Commons](#)

Recommended Citation

Almeida, Aaron M., "The synthesis and evaluation of a more highly conjugated molecular transporter" (2007). *Honors Theses*. 2098.
<https://digitalworks.union.edu/theses/2098>

This Open Access is brought to you for free and open access by the Student Work at Union | Digital Works. It has been accepted for inclusion in Honors Theses by an authorized administrator of Union | Digital Works. For more information, please contact digitalworks@union.edu.

UN
82
A4475
2007

**The Synthesis and Evaluation of a More Highly Conjugated
Molecular Transporter**

By

Aaron M. Almeida

**Submitted in partial fulfillment
of the requirements for
Honors in the Department of Chemistry**

**UNION COLLEGE
June, 2007**

Table of Contents

Introduction:	Page 1-15
Cellular Membrane	Page 1
Drug Design Limitations	Page 1
Protein Study Limitations	Page 2
Molecular Transporters	Page 2
Method of Internalization	Page 4
Hypothesis	Page 6
Our Novel Potential Molecular Transporter	Page 7
N9 Substituted Guanines	Page 7
Peptoids	Page 10
Cellular Assays	Page 13
 Experimental:	 Page 16-23
Guanine Synthesis	
Tetrabutylammonium 2-amino-6-chloropurin-9-ide (1)	Page 16
N ⁷ - and N ⁹ -(2-chloroethyl)-2-amino-6-chloropurine (2, 3)	Page 17
N ⁹ -(2-chloroethyl)guanine (4)	Page 17
N ⁹ -(2-iodoethyl)guanine (5)	Page 18
2-amino-9-(2-(benzylamino)ethyl)-1H-purin-6(9H)-one (6)	Page 18
2-amino-9-(2-(ethylthio)ethyl)-1H-purin-6(9H)-one (7)	Page 18
2-(2-amino-6-oxo-1H-purin-9(6H)-yl)ethyl benzoate (8)	Page 19
2-amino-9-vinyl-1H-purin-6(9H)-one (9)	Page 20
Peptoid Synthesis	
Lysine peptoid analogue with Boc-protected side chains (14)	Page 20
Quantum Dot Conjugation to Peptoids (15).(Proposed)	Page 22
Polylysine peptoids with and without Quantum	
Dots attached (16, 19).(Proposed)	Page 22
Polyarginine Peptoids with and without	
QD's (17, 20).(Proposed)	Page 22
Guanine side-chain Peptoids with and without	
QD's (18, 21). (Proposed)	Page 23
 Discussion:	 Page 24-31
Synthesis:	
N ⁹ -(2-chloroethyl)guanine:	Page 24
N ⁹ -(alkyl)guanine derivatives:	Page 24
Peptoid Synthesis:	Page 25
Cellular Assays:	Page 27
 References:	 Page 32-33
 Figures Appendix	 Page 34-42

Figures

Figure 1: Cartoon of Cell Membrane	Page 1
Figure 2: Ribbon Structure of HIV-tat	Page 2
Figure 3: Arginine	Page 3
Figure 4: Guanidinium moiety	Page 5
Figure 5: Potential Hydrogen Bonding Complexes for the Guanidinium moiety	Page 5
Figure 6: Experimental Potential Molecular Transporter	Page 7
Figure 7: N9 Substituted Guanine	Page 7
Figure 8: Synthetic Scheme for N9-(2-chloroethyl)guanine	Page 8
Figure 9: Synthesis of N9-(2-chloroethyl)guanine derivatives	Page 9
Figure 10: Peptide vs. Peptoid structure	Page 10
Figure 11: Synthetic Scheme of Peptoid Backbone 10-12	Page 11
Figure 12: Synthetic Scheme of Peptoid Backbone 13-15	Page 11
Figure 13: Synthetic Scheme of Peptoid Backbone 16-18	Page 12
Figure 14: Synthetic Scheme of Peptoid Backbone 19-21	Page 12
Figure 15: Compounds Incubated with cells for Cellular Assays B-G	Page 14
Figure 16: Uptake of Quantum Dots alone in Interior MDCK Epithelial Cells	Page 28
Figure 17: Uptake of Quantum Dots alone in Peripheral MDCK Epithelial Cells	Page 29
Figure 18: Uptake of Quantum Dots + Polylysine in interior MDCK Epithelial Cells	Page 30
Figure 19: Uptake of Quantum Dots + Polyarginine in Interior MDCK Epithelial Cells	Page 31

Abstract

Molecular transporters are a class of compounds displaying high efficiency for traversing the cellular membrane. Multiple naturally occurring proteins are efficient at crossing the cell membrane and further studies indicated the important regions for inducing cellular uptake are highly cationic, containing multiple arginine amino acids. The guanidinium head group of the arginine side chain appears to be the primary factor in determining uptake efficiency, however the method of internalization is currently unknown. One uptake theory suggests passive diffusion through the formation of less-polar complexes at the membrane surface is responsible for uptake, though the molecular details remain unclear. We aim to elucidate the role of polycationicity in cell penetration. We report the design and synthesis of a peptidic molecular transporter with the highly conjugated, polycationic, guanidine as the pendant side chain. The transporter was synthesized by attachment of a guanidine precursor to a monomer peptide chain. The side chain precursor, 2-chloromethylguanidine, was synthesized in an overall yield of 52 % without chromatography or steric blocking groups. Selective crystallization yielded the desired N9 isomer, eliminating the need for preparative chromatography. Comparative cellular assays with fluorescently tagged peptides were carried out to measure the efficiency of internalization.

Introduction

Cellular Membrane:

Biological membranes evolved over time to prevent the entrance of xenobiotics into the cell.¹ The cell membrane still has to remain permeable to beneficial components however, and so numerous systems for entry into the cell have




Figure 1. Cartoon of Cell Membrane

evolved. Transporters, translocases, permeases, pores, channels, and pumps are a few examples of cellular entry mechanisms involved in allowing desired compounds through the cell membrane.² While

enormously important for the survival of the cell, the cell membrane's selectivity for entrance into the cell limits the development of therapeutics with internal cellular targets. There is substantial interest in the development of methods for facilitating the delivery of molecules into mammalian cells.^{3,4,5}

Drug Design Limitations:

The presence of the nonpolar lipid layer separating the environment from the aqueous internal cavity creates a structural limitation on nascent therapeutics with intracellular targets. Only a very narrow range of hydrophobicities can be used, as drugs must be polar enough to enter the blood, enabling them to travel to the membrane of their target cells, and non-polar enough for diffusion through the cell membrane. Also the molecules must be small enough to diffuse through the cell

membrane, as size indirectly relates to the ability of the molecule to diffuse through the membrane. Structurally speaking limits molecules to less than five hydrogen bonding donor sites, less than 10 hydrogen bond acceptor sites, and a mass less than five hundred a.m.u.,

Protein Study limitations:

Another membrane induced limitation is the *in vivo* study of proteins. Options for delivering functional proteins into cells are limited and often have high toxicity rates due to membrane disruption. While there are methods for introducing transcriptionally active DNA into cells, the method is extremely difficult for a variety of mammalian cells and require several hours if not days to complete.⁶

Molecular Transporters:

A class of compounds known as molecular transporters have recently gained considerable attention for their ability to translocate across the membrane into the cell. First identified from natural proteins such as HIV-1 transcription activator protein (Tat) and the Transcription factor Antennapedia (Antp), they are a class of highly cationic water soluble compounds which maintain their ability to traverse the cell membrane.⁷ The HIV Tat protein is able to rapidly enter the cytosol and nucleus of a wide variety of cells by inducing endocytosis.⁸ A variety of other proteins have also been discovered with the same ability.^{9,10}



Figure 2. Ribbon Structure of HIV-tat




Figure 3. Arginine

In these proteins a small region has been shown to be responsible for the cellular uptake.

This region tends to be highly cationic or

amphipathic. In Tat the highly cationic region Tat₄₉₋₅₇ (RKRRQRQR) has been shown to be primarily responsible for its cellular uptake.¹¹ The protein is no longer capable of entering the cell in the absence of this region. Unlike other proteins capable of entering the cell, the cellular uptake region in molecular transporters retains their activity separate from the protein. It is this unique ability that is showing promise for the delivery of previously unavailable therapeutics into the cell.¹²

Molecular transporters have been shown capable of delivering a wide variety of cargo with sizes up to 500 micrometers. Therapeutics that were otherwise too large, or too polar for the cellular membrane, or too non-polar to travel through the blood stream, would be available for use due to the molecular transporters unique abilities. New target sites with highly polar regions would also become available due to the efficiency of the molecular transporters at cellular uptake and drug delivery. The scope of targeted cells for study would also increase because all previously studied mammalian cell lines have been shown to be receptive to protein transduction. Useful therapeutics, and other cargo unable to cross the cellular membrane could be attached to molecular transporters, carried across the membrane, and then cleanly cleaved from the transporter, free to reach their target site.

Method of internalization:

The mechanism by which molecular transporters cross the cell membrane is still under debate, however multiple theories have been proposed. Early structural studies examined the individual activity of the amino acids in known uptake sequences. Polyhistidine, polyornithine, polylysine and others were found to be ineffective molecular transporters, however polyarginine showed a 20 fold increase in uptake efficiency compared to the natural HIV-Tat sequence. The non-natural D-arginine polypeptide chain showed a 100 fold increase in apparent uptake efficiency, however this is believed to be due to the protease resistance of the poly-D-peptide structure and not due to an increase in uptake efficiency.¹² In examining the structure of arginine, studies showed that a wide variety of structural alterations could be made without significantly affecting the uptake efficiency. A peptide length between 8-16 amino acid residues gives optimal membrane transduction efficiency.¹³ A wide variety of backbone structures have been shown to be effective at traversing the cellular membrane.¹¹ In addition to the natural L-peptides, D-isomer peptides, β -peptides, peptoids, and oligocarbamates have been shown to be effective backbones for molecular transporters despite varying unit lengths, chirality, side chain location, and the inclusion of heteroatoms into the backbone. Molecular transporters with slightly longer side chains have shown increased effectiveness at traversing the membrane, however molecular transporters can have a wide variety of side chain lengths without losing their uptake affinity.¹¹

The guanidinium head group of the arginine amino acid side chain is primarily responsible for the cellular uptake of these HIV-Tat based molecular transporters.

While it is a charged moiety capable of hydrogen bonding, those characteristics alone are not sufficient for activity as neither lysine, ornithine, or histidine homopolymers

possess the ability to traverse the cellular

membrane.¹⁴ It has been suggested by Rothbard *et*

al. that it is the ability of the guanidinium moiety to

donate a bidentate hydrogen bond that is primarily

responsible for its activity.¹¹ This hydrogen




Figure 4. Guanidinium moiety

bonding theory is supported by several studies. Singly N₁-methylated arginine

monomers have a decreased in uptake affinity which correlates to the ability of the methyl

group blocking the position necessary for hydrogen bond donation. Double

N₁, N₃-methylated arginine peptides completely lack the ability to traverse the cellular

membrane.¹² A method of internalization proposed by Rothbard, suggests that the

guanidinium moiety of the arginine side chain forms bi-dentate hydrogen bond

complexes with negatively charged

moieties present on the cell surface.

Figure 5 shows 3 such complexes

which could form. This bi-dentate

hydrogen bond interaction between

positive and negative moieties is

implicated in the uptake as molecular

computers have been shown to




Figure 5. Potential Hydrogen Bonding Complexes for the Guanidinium moiety

have a weaker uptake efficiency in heparin sulfate deficient cell lines.¹⁵ Heparin

sulfate is a glycosaminoglycan (GAG) common to the extracellular matrix of

mammalian cells involved in a wide variety of life essential and nonessential processes.

Rothbard's theory suggests that the formation of the complex allows for an overall neutral complex which is then capable of passive diffusion through the cell. Contrary to earlier studies passive diffusion no longer appears to be the primary mechanism, although there is still evidence that it still can happen. Fixation artifacts present in earlier studies showed diffuse molecular transporters throughout the nucleus and cytosol. Recent studies done with live cells show that molecular transporters localize in endosomes. The ionic interaction between the guanidinium moieties and the sulfate moieties does appear to be the first step involved in the molecular recognition at the cell surface for stimulating endocytosis⁶. However further research must be carried out in order to gain a better understanding the structural characteristics required for the guanidinium moiety's uptake efficiency.

Hypothesis:

Examination of the guanidinium moiety shows two important characteristics which have not been explored in current literature. Its conjugated structure gives it a highly polarizable nature, as well as an ability to effectively distribute charge. Delocalized π -electrons should have a significant effect due to the uptake mechanism's dependence on the interaction between the molecular transporters and negative cell surface moieties. Any change in the nature of the delocalized π -electrons should have a significant effect in the rate of formation for the necessary complex for cell recognition, ultimately affecting the rate of uptake.

Our Novel Potential Molecular Transporter:

In order to explore this effect, we synthesized a novel peptoid chain containing a guanine pendant side chain with the necessary bi-dentate hydrogen bond donating ability, but with increased conjugation, rendering it more capable of resonance and therefore more polarization. Our compound shown in figure 6 is




Figure 6. Experimental Potential Molecular Transporter

generated via a convergent synthesis, synthesized separately, and combined yielding our novel compound.

An N⁹-tethered guanine constitutes the head group of our molecular transporter for direct comparison to the guanidinium moiety of arginine, a peptoid chain constitutes the backbone of our molecular transporter, and a Quantum Dot (QD) fluorophore functions to visualize

our peptoids during live cell assays.

N⁹ Substituted Guanines:

The N⁹ substituted guanine structure is shown in Figure 7. It contains the guanidinium moiety, however its conjugated bicyclic nature extends the polarizability and resonance beyond that capable by an isolated guanidinium




Figure 7. N9 Substituted Guanine

moiety. Current literature establishes the synthesis of N⁹ substituted guanines due to successful biological targeting. N⁹ substituted guanines have been explored and several derivatives are currently used for their anti-viral activity.

Substitution at the N^9 position is a common motif in these guanine derivatives, however selective substitution has been difficult to achieve. Previous syntheses have relied on steric blocking of the N^9 position.¹⁶ Regionspecific N^9 Michael additions have also been employed with a variety of Michael acceptors which favor the more thermodynamically stable N^9 substitution.¹⁷ However nearly all previous syntheses have relied on chromatography to separate the desired N^9 isomer from the N^7 isomer. Geen et al. fractionally recrystallized the desired N^9 isomer after alkylation by 2-acetoxytetrahydrofuran.¹⁸ Bisacchi et al. also use selective crystallization as a key step




Figure 8. Synthetic scheme for N^7 -(2-chloroethyl) guanine

in a cyclobutyl-substituted guanine in their synthesis of BMA5-180,194.¹⁹

The synthetic scheme is shown in Figure 8. Synthesis of our N^7 tethered guanine began with commercially available 2-amino-6-chloropurine and is efficiently achieved without employing chromatography. Substitution at the N^7 position is achieved first by the

addition of tetrabutylammonium(TBA) hydroxide to quantitatively form the N^7 -deprotonated salt of the purine, 1, as carried out by Bisacchi et al.²⁰ Once the TBA salt of the guanine has been formed, alkylation at the N^9 position is achieved by introducing an excess of 1-bromo-2-chloroethane in a CH_2Cl_2 solution. This yielded a 1:5 ratio of N^7 (2), and N^9 (3), regioisomers. Recrystallization of the crude product in

CH_2Cl_2 yielded the N^9 substituted isomer free from impurity. Hydrolysis of 3 in aqueous HCl yields N^9 -(2-chloroethyl)guanine (4), in nearly quantitative yield.

In order to test its electrophilicity and show its synthetic versatility in the synthesis of various N^9 substituted guanine derivatives, 4 was reacted with various nucleophiles, yielding derivatives 5-9. The synthetic scheme for the derivatives is shown in Figure 9. The synthetic versatility of N^9 -(2-chloroethyl)guanine is also important in determining the method by which to attach the guaninyl head group to our peptoid backbone.

Many derivatives of 4 were easily synthesized by the introduction of various




Figure 9. Synthesis of N^9 -(2-chloroethyl)guanine derivatives:
 a. NaI in DMF, 75 C, 1.5 h. b. cat NaI , benzylamine in THF, 60 C, 20 h
 c. cat NaI , triethylamine in NaOH & DMSO, 75 C, 1.5 h
 d. cat NaI , $\text{methylmagnesium bromide}$ in DMSO, 120 C, 3.5 h
 e. cat NaI , NaOH in DMSO, 85 C, 2 h


nucleophiles. The following examples show the versatility of 4 and optimization of yields was carried out by varying the solvent, temperatures and reaction times. Catalytic iodide was used due to its facile

displacement of the chloride, resulting in a shorter reaction time for the subsequent derivatives. Synthetic yields were limited by solvation, and so significant effort was spent in determining an appropriate solvent which was polar enough to solvate the N^9 -tethered guanine, yet still aprotic and non-polar enough to allow for facile nucleophilic attacks. Temperature increases were significant increasing solvation and

in speeding up the reaction to a convenient rate, however competition with the elimination product limited the extent by which the solution could be heated.

Peptoids:

Our lab was interested in synthesizing a novel molecular transporter with high



Peptide

Peptoid

Figure 10. Peptide vs. Peptoid Structure

protease resistance to lower the experimental uncertainty introduced by protease degradation in live cells. We also wanted a backbone that had been previously shown to function as a

backbone for MT's. Peptoids were chosen due to their increased flexibility in introducing a wide variety of side chain structures, giving increased flexibility in determining the method by which to attach the guanine head group to the backbone.

The nitrogen substitution pattern of peptoids introduces too much steric bulk around




Figure 11. Synthesis of Peptoid Backbone (13) from Fmoc-protected amino acid 12. A. 2-Chlorotritylchloride resin, B. 12, C. Peptoid Backbone (13)

the amide nitrogens for facile bond cleavage by proteases.²¹ The synthesis of the peptoid backbone can be achieved using solid phase synthesis with an orthogonal protecting strategy according to Figure 11. 2-Chlorotritylchloride functionalized polystyrene resin was used as the solid phase anchor for the

synthesis. 2-Chlorotritylchloride resin was chosen due to its lability under mild acid conditions, allowing for selective deprotection in the presence of other acid labile protecting groups. Loading of 6-(Fmoc-amino) caproic acid allowed for monitoring

the loading of the resin, while also acting as a spacer to decrease the on-resin steric effects, yielding 5. Excess bromoacetic acid was activated using DIC and then introduced to the resin for the formation of an amide bond. Excess N-Boc-1,6-diaminohexane displaced the bromide on the resin yielding the first residue 11, with a protected side-group preventing any undesired side-reactions. Repeating the introduction of DIC activated bromoacetic acid followed by N-boc-1,6-diaminohexane 8 times gives a peptoid with the desired 9 residues 12. N-capping of the peptoid was achieved with acetic anhydride, preventing any further reaction at the N-terminus 13.

Our amine functionalized Quantum Dot fluorophore was obtained from Evident Technologies, and the attachment protocol for peptide analogues is composed of activating the C-terminus, and introducing the Quantum Dots with their amine functional groups.




Figure 12. Synthesis of Peptoid Backbone 13-15. a. acetic anhydride
b. 0.5 % TFA
c. EDC. d. Amine functionalized QDs




Figure 13. Synthesis of Peptides 16-18. a. Weak Acid
b. Pyrazole-1-carboxamide, heat 24 h
c. N9-(2-chloroethyl)guanine




Figure 14. Synthesis of Peptides 19-21 a. Weak acid
b. Pyrazole-1-carboxamide, heat 24 h
c. i. DIC, ii. Amine functionalized QD's

For this reason it is necessary to keep the side chains of our peptoid protected until attachment to Quantum Dots, otherwise activation of the C-terminus would result in side chain amine group coupling, instead of the desired coupling with the Quantum Dots.

Cleavage from the 2-Chlorotritylchloride resin was achieved in 0.1% TFA, leaving the Boc protecting groups intact 14. Coupling to the Quantum Dots was carried out according to the Evident technology protocol 15, using size exclusion to filter the excess uncoupled peptides, and purify our desired Quantum Dot-peptoid complex 16.

After attachment to the Quantum dots, deprotection of the boc protecting group yields a polylysine peptoid analogue 17, which will function as our negative control in our cellular assay. Guanidinylation of 17 was carried out as described by Wender, yielding the polyarginine peptide analogue 18, to function as our positive control in the cellular assay. Synthesis of 19, 20, and 21 the analogues without a QD fluorophore were carried by skipping the Quantum Dot attachment protocol and combining the cleavage from the resin and boc-deprotection into one step. The experimental peptoid 21 was synthesized by nucleophilic attack of 12's side chains on 5 (N²-(2-chloroethyl)guanidine). However further synthetic efforts were delayed by degradation of the 2-Chlorotrityl chloride resin in methylene chloride and DMF. Significant Uv-Absorption occurred after stirring resin in the solvent which is presumed to be due to the trityl group, or the polystyrene fragments.

Cellular assay:

To test the molecular transporter efficiency of our experimental peptoid, multiple different control tests, as well as our experimental peptoid were incubated in MDCK cells and examined by microscopy. Mancy-Darbin Canine Kidney (MDCK)

cells were used due to their specialization in absorption and secretion. Live cells were observed due to experimental artifacts introduced by fixation.⁸




Figure 18. Compounds incubated with cells for Cellular Assays B-G

There are four controls shown in Figure 14 (B,C,E,F) as well as our two experimental (D,G) to determine the molecular transport ability of our experimental peptoid. The cell assay procedure (A-G) involved incubating MDCK cells in a solution containing the compounds of interest (16-21), rinsing the cells after the incubation period has passed, to remove QD fluorescence external to the cell, and then examining the cells by microscopy to determine the quantity and location of the fluorophore within the cells. The first cell assay will be to determine how quantum dots act when they are incubated alone with the cells. Cell assay B consists of incubating 16 with MDCK cells, to act as a standard without molecular transport ability. In cell assay C, we incubate 17 in MDCK cells to act as a standard with known molecular transport affinity. Control tests E, and F were carried out as a comparison to B, and C, differing in that the QD fluorophore is not attached to the

molecular transporter in D, and E, but is still present in the solution. This will give insight into the different mechanisms by which the molecular transporters function. If F results in the cells having the same concentration of quantum dots in the cell as external to the cell, then it would lend evidence that the molecular transporters are disturbing the membrane, and allowing for anything to travel through, which is significantly different than a discreet delivery mechanism. If no quantum dots in F are able to enter the cells then it would lend evidence that there is a specific mechanism by which the molecular transporters are able to enter, but which doesn't allow for the entry of anything else. By endocytosis it is also likely that F would result in a small amount of quantum dots present in the cells that were nearby and were pinched off into the cells when endocytosis occurred. Cell assay D, will give insight into the molecular transport efficiency of our novel peptoid, with high internal quantum dot concentrations corresponding to a high molecular transport ability, and low internal quantum dot concentration corresponding to low molecular transport ability. Cell assay G will give information on whether our compound functions any differently than 2D and 17 in Assays C & F.

EXPERIMENTAL

General

All purchased reagents were used without further purification. Thin-Layer Chromatography (TLC) was performed on Selecto Scientific Silica Gel 60, F-254 TLC plates. Melting points were obtained using a Laboratory Devices MEL-TEMP and are uncorrected. $^1\text{H-NMR}$ spectra were obtained using a Varian Gemini-200 (200 MHz). Chemical shifts are reported as δ in ppm referenced to the solvent residual peak of DMSO- d_6 (δ 2.50) unless otherwise noted.

N9-(2-chloroethyl)guanine;

Tetrabutylammonium 2-amino-6-chloropurin-9-ide (1). Procedure was adapted from Bisacchi *et al.* Aqueous tetrabutylammonium hydroxide (~1.5 M, 39.3 mL, ~59 mmol) was added to a slurry of 2-amino-6-chloropurine (10.0 g, 59 mmol) in 250 mL of CH_2Cl_2 . The reaction mixture was stirred for 30 min and the solvent removed *in vacuo*. Concentration from toluene (3×100 mL) allowed for the removal of water and resulted in crystallization. The solid was triturated with 200 mL of ether, filtered, washed with ether, and dried under vacuum over CaSO_4 to yield **1** (24.4 g, 59 mmol, 100%). The orange solid was used without further purification: mp 66-70 $^\circ\text{C}$; R_f = 0.60 ($\text{CHCl}_3/\text{EtOAc}/\text{EtOH}$ 1:1:1); $^1\text{H-NMR}$ (DMSO- d_6), referenced to TMS δ 0.00) δ 0.60 (CHCl₃/EtOAc/EtOH 1:1:1); $^1\text{H-NMR}$ (DMSO- d_6), referenced to TMS δ 0.00) δ 0.92 (12H, t), 1.28 (8H, m), 1.58 (8H, m), 3.16 (8H, m), 5.38 (2H, s), 7.55 (1H, s). $^{13}\text{C-NMR}$ (DMSO- d_6 , δ): 167.0, 157.8, 156.6, 145.4, 128.0, 58.5, 24.0, 20.1, 14.4.

N⁷- and N⁹-(2-chloroethyl)-2-amino-6-chloropurine (2, 3). To a solution of **1** (10.0 g, 24 mmol) in 30 mL of CH₂Cl₂ was added 1-bromo-2-chloroethane (10 eq, 19.9 mL, 240 mmol). The reaction mixture was stirred at 60°C for 2 h, during which time precipitation occurred. The solid was filtered, washed with cold CH₂Cl₂, and dried under vacuum over CaSO₄ to yield a 1:5 mixture of **2** and **3** (4.78 g, 20 mmol, 85% combined yield). Recrystallization from CH₂Cl₂ (~20 mL) provided 3.70 g of the N⁹ isomer, **3**, free of contamination with N⁷ isomer **2**: mp 189-191 °C; R_f = 0.65 (CHCl₃/EtOAc/EtOH 1:1:1); ¹H-NMR (DMSO-*d*₆) δ 4.04 (2H, t), 4.41 (2H, t), 6.99 (2H, s), 8.17 (1H, s). Compound **2**: R_f = 0.49 (CHCl₃/EtOAc/EtOH 1:1:1); The ¹H-NMR spectrum of **3** was consistent with that reported previously. ¹H-NMR (DMSO-*d*₆) δ 8.17 (1H, s), 6.977 (2H, s), 4.42 (2H, m), 4.05 (1H, m). ¹³C-NMR (DMSO-*d*₆, δ): 159.8, 154.1, 149.5, 143.3, 123.3, 44.8, 42.5. MS *m/z* (relative intensity): 231.0 (56%), 196.0 (22%), 169.0 (100%), 146.0 (16%), 134.0 (45%), 84.0 (39.0%), 66.0 (48%). HRMS (*m/z*): [M]⁺ calcd for C₇H₇N₅Cl₂, 231.0079; found, 231.0083.

N⁹-(2-chloroethyl)guanine (4). A solution of 3 M HCl_(aq) (13 mL), containing **3** (2.5 g, 10.8 mmol), was refluxed for 1 h. The solution was cooled to rt and neutralized with saturated NaHCO_{3(aq)}. The resulting solid was filtered, washed with cold water, and dried under vacuum over CaSO₄ to yield **4** (2.31 g, 10.8 mmol, 100%): mp >250 °C; R_f = 0.24 (CHCl₃/EtOAc/EtOH 1:1:1); ¹H-NMR (DMSO-*d*₆) δ 3.97 (2H, t), 4.29 (2H, t), 6.53 (2H, s), 7.74 (1H, s), 10.70 (1H, s). MS *m/z* (relative intensity): 213.0 (100%), 177.0 (28%), 151.0 (96.5%), 109.0 (63.0%). HRMS (*m/z*): [M]⁺ calcd for C₇H₈ON₅Cl, 213.04174; found, 213.04192.

N⁹-Q-indolyl-lysine (5). A solution of 4 (100 mg, 0.468 mmol) containing NaI (10 eq, 791 mg, 4.68 mmol) in DMF (2-3 mL) was stirred at 75 °C for 1.5 h. The DMF was removed under vacuum. The resulting solid was triturated with water, filtered, washed with water, and dried under vacuum over CaSO₄ to yield 5 (110 mg, 0.361 mmol, 77%); mp >250 °C; ¹H-NMR (DMSO-*d*₆) δ 3.56 (2H, t), 4.29 (2H, t), 6.49 (CH, s), 7.72 (1H, s), 10.59 (1H, s). MS *m/z* (relative intensity): 304.9 (1%), 253.7 (46%), 177.0 (100%), 127.9 (100%), 91.0 (8%), 63.4 (7.5%) HRMS (*m/z*): [M]⁺ calcd for C₁₀H₉N₂ 304.9774; found, 304.9773.

2-amino-9-((4-oxophenyl)ethyl)-1H-purin-6(9H)-one (6). Benzylamine (4 eq, 1.87 mmol, 394 μL) was added to a solution of 4 (100 mg, 0.469 mmol) containing NaI (21 mg, 0.140 mmol) in THF (~5 mL). The solution was then stirred for 20 h at 60 °C. After cooling the reaction mixture to rt, acetone (~20 mL) was added, resulting in precipitation. The solid was filtered, washed with acetone, and dried under vacuum over CaSO₄ to yield 6 (112 mg, 0.394 mmol, 84%); ¹H-NMR (DMSO-*d*₆) δ 3.24 (CH, t), 4.11 (1H, s), 4.28 (2H, t), 6.66 (2H, s), 7.43 (5H, m), 7.70 (1H, s), 8.77 (1H, s), 10.76 (1H, s).

2-amino-9-((4-ethylthio)ethyl)-1H-purin-6(9H)-one (7). NaI (21 mg, 0.140 mmol) and 4 (100 mg, 0.468 mmol) were added to a solution of NaOH (4 eq, 1.87 mmol, 75 mg) and ethanol (4 eq, 1.87 mmol, 138 μL) in DMSO (1 mL). The resulting solution was stirred at 75 °C for 1 h and then cooled to rt. Water (~20 mL) and

glacial acetic acid (0.1 mL) were added until precipitation occurred. The resulting solid was filtered, washed with water, and dried under vacuum over CaSO_4 to yield **7** (66 mg, 0.276 mmol, 59%): $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, referenced to HOD δ 3.30) δ 1.09 (3H, t), 2.45 (2H, q), 2.82 (2H, t), 4.05 (2H, t), 6.39 (2H, s), 7.64 (1H, s), 10.51 (1H, s). $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ 157.9, 154.5, 152.1, 138.7, 117.4, 43.4, 31.1, 25.6, 15.6. MS m/z (relative intensity): 307.1 (8.5%), 239.0 (76%), 210.0 (32%), 179.0 (79%), 151.0 (100%), 109.0 (40%), 89.0 (58%), 62.0 (48%) HRMS (m/z): $[\text{M}]^+$ calcd for $\text{C}_9\text{H}_{13}\text{ON}_3\text{S}$ 239.0841; found, 239.0838.

2-(2-amino-6-oxo-1*H*-purin-9(6*H*)-yl)ethyl benzoate (8). A solution of **4** (100 mg, 0.468 mmol) containing NaI (21 mg, 0.140 mmol) and sodium benzoate (4 eq, 1.87 mmol, 270 mg) in $\text{DMSO-}d_6$ (2-3 mL) was stirred at 120-130 °C for 3.5 h. Water (~20 mL) was added to the hot reaction mixture and a precipitate formed. The solid was filtered, washed with water, and dried under vacuum over CaSO_4 to yield **8** (54 mg, 0.180 mmol, 39%): R_f = 0.32 ($\text{CHCl}_3/\text{EtOAc}/\text{EtOH}$ 1:1:1); $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ 4.36 (2H, t), 4.56 (2H, t), 6.47, 7.50 (2H, t), 7.65 (1H, t), (2H, s), 7.77 (1H, s), 7.91 (2H, d), 10.58 (1H, s). $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ 165.5, 157.0, 153.8, 151.5, 139.9, 137.9, 133.6, 129.4, 128.9 (C_{12}), 116.6, 63.1, 42.0, MS m/z (relative intensity): 299.0 (12.0%), 179.0 (20.0%), 165.0 (35.5%), 152.0 (30.0%), 133.1 (12.5%), 105.0 (27.5%), 91.0 (100%), 66.0 (68.5%). HRMS (m/z): $[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{13}\text{O}_3\text{N}_5$ 299.10185; found, 299.10157.

2-amino-9-vinyl-1H-purin-6(9H)-one (9). A solution of **4** (100 mg, 0.468 mmol) containing NaI (21 mg, 0.140 mmol) in DMSO (1 mL) was treated with NaOH (4 eq, 1.87 mmol, 75 mg) and stirred at 75-85 °C for 1.5 h. The resulting precipitate was cooled to rt and dissolved in water (~5 mL). Precipitation occurred following addition of glacial acetic acid (~1 mL). The purple solid was filtered, washed with water, and dried under vacuum over CaSO₄ to yield **9** (68 mg, 0.384 mmol, 82%): ¹H-NMR (DMSO-*d*₆) δ 5.02 (1H, d), 5.85 (1H, d), 6.57 (2H, s), 7.05 (1H, q), 8.08 (1H, s), 10.73 (1H, s). ¹³C-NMR (DMSO-*d*₆) δ 157.0, 154.3, 150.4, 134.7, 126.9, 102.9, 96.6, 22.6. MS *m/z* (relative intensity): 177.0 (81.0%), 78.0 (82.0%), 62.9 (100%) HRMS (*m/z*): [M]⁺ calcd for C₇H₇ON₅, 177.06507; found, 177.06501.

Peptoid Backbone:

General: 2-chlorotriyl Chloride resin was purchased from NovaBiochem. Quantum Dots were obtained from Evident Technologies. Spin filters were obtained from the Union Biology Department.

Synthesis of lysine peptoid analogue with Boc-protected side chains (14).

A sub-monomer approach was employed in peptoid synthesis. Peptoids were manually synthesized in fritted vessels using mechanical agitation to ensure mixing. A chloranil test for secondary amines was performed after each completion of a residue to test for the presence of secondary amines. Agitation of the 2-chlorotriyl Chloride resin (45.5 mg) in DCM (4-5 ml) for 30 minutes exposed approximately 50

μ mol of trityl functional group. Treatment of the exposed trityl group with DCM/MeOH/DIPEA (17:2:1, 2-3 ml) yielded the active resin. The resin was then washed with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3) before being treated with a solution of 6-(N-FMOC)caproic acid (20 eq) and DIC (26 eq) in DCM (4 ml) to yield 10. The resin was then washed again with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3). Treatment with 20% (v/v) piperidine/DMF (1-2 ml for 1 min, 2-3 ml x 5 for 10 min, and 2-3 ml for 10 min) to yield an exposed amine group. UV-vis was used on the wash solution to determine loading effectiveness. The resin was then washed with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3). A solution of bromoacetic acid (20 eq) and DIC (26 eq) in DCM (4 ml) was added to the resin and agitated for 45 minutes. The resin was then washed with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3). A solution containing *N*-Boc-1,6-hexanediamine (17 eq) in DCM (4 ml) was agitated for 45 minutes to yield 11. The resin was then washed with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3). The bromoacetic acid and amine substitution steps were repeated until a 9-residue oligomer, 12, had been obtained. A solution of Acetic Anhydride 5% (v/v) in DMF was added to the resin and agitated for 45 minutes to yield 13. The resin was then washed with DCM (2-3 ml x3), then DMF (2-3 ml x3) and again with DCM (2-3 ml x3). Treatment of the resin with 0.1 % TFA in DMF at 0°C for 4 hours yielded 14. TFA was removed *in vacuo* and the crude oil was triturated with cold ether (20 ml) and centrifuged. The ether was removed by decantation. HPLC analysis showed little impurity and so no further purification was used.

Quantum Dot Conjugation to Peptoids (15).(Proposed)

Conjugation to the Quantum Dots was achieved by the Evident Technologies Protocol. **14** was dissolved in a phosphate buffer system (PBS) (1 ml, pH 7.00) with EDC (5000 eq.). The Quantum Dot solution (~0.1 ml, 12:1 peptoids : Quantum Dots ratio) was added to the peptoid solution. 10x PBS (0.05 ml) was then added to solution. Deionized water was then added until the total solution volume reached 0.5 ml. The peptoids were then incubated with agitation for 2.5 hours to yield **15**. Weight discriminatory spin filters (10 min) separated the unconjugated peptoids, from the Quantum Dot conjugated complex. Rinsing with H₂O (0.3 ml x2) with spin filtering yielded pure peptoids.

Polylysine peptoids with and without Quantum Dots attached (16, 19).(Proposed)

A solution of **15** (1 ml, 50 μ mole) in H₂O with Acetic Acid (1 M, 0.1 ml) yields **16**. Treatment of **14** (1 ml, 50 μ mole) in H₂O with Acetic Acid (1 M, 0.1 ml) yields **19**. Remove acetic acid *in vacuo* and triturate the crude oil with cold ether (20 ml) and centrifuge. Decant the cold ether

Polyarginine Peptoids with and without QD's (17, 20).(Proposed)

Perguanidinylation of **16** and **19** will be carried out as described by Wender *et al.*²⁸ to yield **17** & **20** respectively.

Guanine side-chain Peptides with and without QD's (18, 21). (Proposed)

Guaninylation of 16 and 19 will be carried out by stirring a solution of 16 and 19 with N⁹-(2-chloroethyl)guanine (4) (10 eq) containing NaI (21 mg, 0.140 mmol) in THF (~5 mL). The solution was then stirred for 20 h at 60 °C. After cooling the reaction mixture to rt, add acetone (~20 mL), resulting in precipitation. Filter the solid, wash with acetone, and dry under vacuum over CaSO₄.

Synthesis:

N^9 -(2-chloroethyl)guanine:

Our easily scalable synthesis which is able to avoid chromatography and blocking groups for alkylation allowed for an efficient synthesis of N^9 -(2-chloroethyl)guanine with an overall yield of 58%. N^9 -(2-chloroethyl)guanine was also shown to be a versatile reagent in synthesis of other N^9 -substituted guanines.

N^9 -(alkyl)guanine derivatives:

N^9 -(2-chloroethyl)guanine reacted readily with various nucleophiles. The Finkelstein reaction readily yielded the corresponding iodo form, 5, in high yield (77%), and so NaI was used as a catalyst in the subsequent reactions. 6 readily formed by substitution with a primary amine (benzyl amine) in high yield (84%) and shows promise for the intended pathway for guanylation of the peptoids to yield 18 and 21. 7 and 8 were also formed in good yield by substitution with a thiol (59%), and benzoate (39%), respectively. The elimination product 9, (82%) also readily formed in high yield. The solvent played a large role in determining the rate of reaction. The polarity of guanine requires a polar solvent, which indirectly affects the rate of reaction. Significant optimization of the reactions occurred in determining an appropriate solvent to carry out the reactions. Temperature also proved an important factor in optimizing yields of these reactions however competition with elimination limited the extent to which the reaction could be heated. The model chemistry showed that N^9 -(2-chloroethyl)guanine is a versatile reagent which could be used in the synthesis of a wide range of N^9 -substituted guanines.

Peptoid Synthesis:

The synthesis of our peptoids is based on a submonomer approach with orthogonal protection scheme allowing for the inclusion of a wide variety of side-chains into the peptoid structure as well as selectivity and control in determining the location of the functional groups affected by the reactions. This allows us to build our peptoids off of the N-terminus of the peptoid. coupling bromoacetic acid to the N-terminus amine, without affecting the side-chain amines. Selectivity in this step was critical for building our linear peptoids. Selective coupling of the C-terminus carboxylate group to the amino functionalized quantum dots is also critical to our synthesis. The orthogonal protecting scheme allows the C-terminus to selectively react with the amino groups attached to the quantum dots. Without the protecting groups, the activated ester would favor coupling to a side chain amino group, which is more immediately available and present in higher concentration than the quantum dot amino groups.

The 2-chlorotriyl Chloride resin was chosen as the solid-phase anchor for the peptoid synthesis due to its lability under mildly acidic conditions. Its mild lability allowed the use of the boc protecting group on the side chains, which must remain unaffected by the cleavage from the resin. The resin was expected to act as a stable anchor, however UV-Vis spectroscopy of DMF and CH_2Cl_2 solutions stirred with resins showed evidence of degradation, possibly fragments of polystyrene or trityl groups. This emphasizes the importance of examining the progress of the reactions over the course of the peptoid synthesis.

FMOC de-protection allows for UV-Vis examination of the solution for the presence of the dibenzofulvene adduct. In our synthesis this was used to test the

effectiveness of the 6-(Fmoc)-capric acid loading onto the resin. The Chloranil test, which is effective at detecting the presence of primary and secondary amines, can be used to determine the effectiveness in building each section of the residues. A negative test after coupling out the nucleophilic attack of 1,6-FMOC-diaminohexane on the peptoid residue, shows the successful conversion into the secondary amine in the backbone. A negative test result after coupling benzoic acid onto the peptoid chain shows successful conversion into the backbone amide.

The N-terminus was capped with benzoic acid to prevent any side reactions during the rest of the synthesis. This was designed to prevent any coupling of the N-terminus to other activated C-termini during the quantum dot coupling step, but applies to any reaction, after the desired number of residues have been synthesized, involving the N-terminus.

Coupling the peptoid to the quantum dot was carried out with the peptoids in slight excess. There is an average of 10 amino functional groups present on Fort Orange amine QDs, and so 12 equivalents of peptoids were added per quantum dot in the synthesis of compound 15. It was important to ensure that all of the quantum dots were coupled to peptoids due to the extremely difficult task of separating the conjugated quantum dots from the unconjugated quantum dots. Any uncoupled peptoids can easily be separated from the quantum dot complexes using a mass discriminatory spin filter. The large mass of the quantum dots complexes provides a simple method for purification from the much smaller side products of the subsequent reactions which yield 16, 17, and 18.

Perguanidinylation of the peptoids has been carried out on 19 to yield 20, but has not yet been carried out on 16 to yield 17. Purification of 20 was carried out by RPLC. and significant time could be saved by determining a smoother method. 17 has not yet been synthesized, however due to its large mass, a weight discriminatory spin filter is expected to provide an acceptable purification method. This same method is expected to be efficient in the purification of the guaninylated peptoid 18, however it is expected that RPLC will have to be used to purify 21.

Cellular Assays:

There are 7 different tests (A-G) which should be carried to assess the ability of the guaninylated peptoids 18 and 21 to enter the cell. The cell assay procedure involves incubating MDCK cells in a solution containing the compounds of interest (16-21), rinsing the cells after the incubation period has passed, to remove QD fluorescence external to the cell, and then examining the cells by microscopy to determine the quantity and location of the fluorophore within the cells. In the preliminary tested carried out so far microscopy was used to determine the location of the QD's. Assay A. contains a solution of quantum dots to assess their activity when incubated with the cells alone. Assays B-G each contain one of the peptoid compounds synthesized (16-21). Cells assays E-G, which contain compounds 19-21, have a solution of quantum dots added to yield the same concentration of fluorophore as Assays A-D.

Figure 15 shows the results from Assay A when carried out on interior MDCK cells. Examination of the images show that no quantum dots appear to have entered




Figure 15. Uptake of Quantum Dots Alone in Interior MDCK Epithelial Cells - MDCK cells treated with 0.05 mM QDs and incubated at 37°C with 5% CO₂ in humidified air for 90 minutes. Image (A): Phase contrast image Image (B): Fluorescent image Image (C): Merged image of (A) and (B) The scale bar (1 cm) corresponds to 17.5 mm seen by the 100x objective

the cells. This can be inferred due to the differences in focus. The focus of the microscope is aligned upon the cells, and any quantum dots in focus are considered being in the same level as the cells, while those out of focus are above or below the cells. Any quantum dots found in focus in the same spot as a cell could only be there because it is inside the cell. Out of focus quantum dots in the same spot as cells are above or below, but not inside the cell. Examination of Image C in Figure 15 shows that there does not appear to be any quantum dots that could be considered inside the cells. This figure shows that in the subsequent assays, any cells which contain quantum dots within them, is due solely to the activity of the peptoids attached to them, as quantum dots are




Figure 16. Uptake of Quantum Dots (QDs) in
 Morphant MDCK Epithelial Cells - MDCK cells
 treated with (10⁻⁶ M) QDs and incubated at 37 °C
 with 5% CO₂ atmosphere for 90 minutes. Image
 (A): Phase contrast image (B): Fluorescent
 image (C): Micrograph image (D): The
 cells were also covered with 10⁻⁶ M QDs by the
 100% aqueous

incapable of entering the cells on their own. Figure 16 shows a second run of Cell Assay
 A with periphery MDCK cells, which gives the same result, having no quantum dots
 present within the cell. Figure 16 also differs from Figure 15 in that there appears to be
 some quantum dots attached to the sides of the cells, but this is expected considering the
 large number of negative cell surface molecules and the positive amino groups present on
 the quantum dot surface. The quantum dots are still on the exterior of the cell, and so this
 shows further evidence that the quantum dots can not enter the cells.

The cell assays B-D and G have not yet been carried out due to the chloroformyl
 chloride resin degradation delaying the peptide synthesis plans. However Cells Assays E
 and F have been carried out and show promising results.

Figure 17 shows the results from Cell Assay E. Examination of the cells shows the quantum dots non-specifically bound to the cell membrane of the cells, however no quantum dots appear to have entered the cells.




Figure 17. Uptake of Quantum Dots + Polylysine in Interior MDCK Epithelial Cells - MDCK cells treated with 0.05 mM QDs and incubated at 37°C with 5% CO₂ in humidified air for 90 minutes. Image (A) Phase contrast image Image (B): Fluorescent image Image (C): Merged image of (A) and (B) The scale bar (1 cm) corresponds to 17.5 mm seen by the 100x objective

This shows that compound 19 provides a good negative for the test because no quantum dots were able to enter the cells. We are unable to see the peptoids themselves, however this shows that the poly lysine does not appear to induce endocytosis, which would result in some quantum dots entering the cells. This provides a good contrast for the subsequent assays for comparison to Assays F & G with compounds 20 and 21.

Figure 18 shows the results from Cell Assay F.




Figure 18. Uptake of Quantum Dots + Polyarginine in Interior MDCK Epithelial Cells - MDCK cells treated with 0.05 mM QDs and incubated at 37°C with 5% CO₂ in humidified air for 90 minutes. Image (A): Phase contrast image Image (B): Fluorescent image Image (C): Merged image of (A) and (B) The scale bar (1 cm) corresponds to 17.5 mm seen by the 100x objective

We are unable to see the peptoids in this assay, and so we can not yet speculate on their location in the cell, however this cell assay offers encouraging results due to the presence of some quantum dots within the cells. This suggests that the peptoids are inducing endocytosis. The endocytosis traps quantum dots which are nearby, resulting in their entry into the cells. The differences between this assay and cell Assay E will provide a good basis for determining the efficiency, and possibly any differences in delivery mechanism.

References:

1. Pratt, C. W.; Cornelly K.; *Essential Biochemistry*, 2004. Wiley
2. Kelly, J. L.; Krochmal, M.P.; Scaeffler, H.J., Purine acyclic nucleosides. Nitrogen isosteres of 9-[(2-hydroxyethoxy)methyl] guanine as candidate antivirals. *J. Med Chem.* 1981, 24, 1528-1531.
3. Denicourt, C.; and Dowdy, S.F. Protein transduction technology offers novel therapeutic approach for brain ischemia, *Trends Pharmacol. Sci.* 2003 24, 216-218
4. Leifert, J.A. and Lindsay Whitton, J.) "Translocatory Proteins" and "protein transduction Domains: a critical analysis of their biological effects and underlying mechanisms, *Mol/ Ther.* 2003, 8, 13-20
5. Schwarze, S.R.; Hruska, K. A.; Dowdy, S.F.) Protein Transduction: unrestricted delivery into all cells? *Cell Bio.* 2000, 10, 290-295
6. Thierry, A. R.; Vives, E., Richard, J. P. Prevot, P., Martinandiani, C., Robbins, L. and Lebleu, B. Cellular uptake and intracellular fate of antisense oligonucleotides. *Curr. Opin. Mol. Ther.* (2003) 5, 133-138.
7. Martin J.C.; Jeffrey, G.A.; McGee, D.P.C.; Tippie, M. A.; Sauer, D.F.; Mathews, T.R.; Verheyden, J.P.H., Acyclic analogs of 2'-deoxynucleosides related to 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine as potential antiviral agents. *J. Med Chem.* 1985, 28, 358-362
8. Fuchs, M.S.; Raines, R.T.; Pathway for Polyarginine Entry into Mammalian Cells. *Biochemistry*, 2004, 43, 2438-2444
9. Kim, C.V.; Luh, B.Y.; Martin, J.C. Synthesis and antiviral activity of (S)-9-[4-hydroxy-3-(phosphonomethoxy)butyl]guanine. *J. Med Chem* 1990, 33, 1797-1800
10. Hakimelahi, G.H.; Ly, T.W.; Moosavi-Movahedi, A.A.; Jain, M. L.; Zakerinia, M.; Davari, H.; Mei, H.; Sambaiah, T.; Moshfegh, A.A.; Hakimelahi, S. Design, Synthesis, and Biological Evaluation of Novel Nucleoside and Nucleotide Analogues as Agents against DNA Viruses and/or Retroviruses. *J. Med. Chem.* 2001, 44, 3710-3720.
11. Rothbard, J.B.; Jessop, T.C.; Lewis, R.S.; Murray, B.A.; Wender, P.A.; Role of Membrane Potential and Hydrogen Bonding in the Mechanism of Translocation of Guanidinium-Rich Peptides into Cells. *J. ACS*, 2004.
12. Futaki, S. et. al. Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. *J. Biol Chem*, 2001, 276(8): p. 5836-40
13. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; and Rothbard, J.B.; 2000. 97. 13003-13008.
14. Derossi, D.; Joliet, A. H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. *J. Biol. Chem.* 1994, 269, 10444-10450
15. Goncalves, E., Kitas, E. et al. (2005). Binding of oligoarginine to membrane lipids and heparin sulfate: structural and thermodynamic characterization of a cell-penetrating peptide." *Biochemistry*, 44(7): 2692-2702

16. Torii, T.; Shirigami, H.; Yamashita, K.; Suzuki, Y.; Hijiya, T.; Kashiwagi, T.; Izawa, K. Practical Synthesis of penciclovir and famciclovir from N2-acetyl-7-benzylguanine. *Tetrahedron*, 2006, article in press
17. Green, G.R.; Kinney, P.M.; Choudary, B.M. Regiospecific Michael Additions with 2-amino purines. *Tetrahedron Lett.* 1992, 33, 4609-4612
18. Geen, G.R.; Kinney, P.M.; Spoor, P.G. Regioselective alkylation of guanines using 2-acetoxytetrahydrofurans. *Tetrahedron Lett.* 2001, 42, 1781-1784.
19. Bisacchi, G.S.; Geen, G.R.; Ramsay, T.W.; Share, A.C.; Slater, G. R.; Smith, N. M. *Tetrahedron* 2000, 56, 4589-4595
20. Bisacchi, G.S.; Singh, J.; Godfrey, Jr., J.D.; Kissick, T.P.; Mitt, T.; Malle, M.F.; Di Marco, J.D.; Gougoutas, J.Z.; Mueller, R.H.; Zahler, R. Regioselective Coupling of Tetraalkylammonium salts of 6-iodo-2-aminopurine to a Cyclobutyl Triflate: Efficient Preparation of homochiral BMS-180,194, a Potent Antiviral Carbocyclic Nucleoside. *J. Org. Chem.* 1995, 60, 2902-2905.
21. Murphy, J.E.; Uno, T.; Hamer, J.D.; Cohen, F.E.; Dwarki, V.; Zuckerman, R.N.; *A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery*, PNAS, 1998(95), 1517-1522.
22. Hury, D.M.; Okabe, M.; AIDS driven nucleoside chemistry, *Chem Rev.* 1992 92, 1745-1768
23. Franchetti, P.; Sheikh, G.A.; Capellacci, L.; Grifantini, M.; De Montis, A.; Piras, G.; Loi, A.G.; La Colla, P. *J. Med. Chem.* 1995, 38, 4007-4013
24. Bonetta, L. *The Scientist* 2002, 16, 38
25. Frankel, A. D.; Pabo, C.O. *Cell* 1988, 55, 1189-1193
26. Krenitsky, T.A.; Hall, W.W.; De Miranda, P.; Beauchamp, L.M.; Schaffer, H.J.; Whiteman, P.D.; Proc. Natl. Acad. Sci. USA 1984, 81, 3209-3213.
27. Müller S M, Simon R J, Ng S, Zuckermann R N, Kerr J M, Moos W H. *Drug Dev Res.* 1995;35:20-32
28. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, B.J.; The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, *PNAS*, 2007, 97, 13003-13008.

Figure Appendix



Figure 1. Cartoon of Cell Membrane




Figure 2. Ribbon Structure of HIV-tat




Figure 3. Arginine




Figure 4. Guanidinium moiety




Figure 5. Potential Hydrogen Bonding Complexes for the Guanidinium moiety




Figure 6. Experimental Potential Molecular Transporter




Figure 7. N9 Substituted Guanine




Figure 10. Synthesis of 4,4'-bis(3-aminopropyl) biphenyl




Figure 11. Synthesis of 4,4'-bis(3-aminopropyl) biphenyl




Figure 12. Poly(amide), Poly(ester) Structure




Figure 11. Synthesis of Peptid Backbone 10-12. a. 4-OT-DBOC-protected Amino Acid
b. 1. Boronate and a DIC; c. N-Boc-L-Aspartic Acid
d. Deprotection




Figure 12. Synthesis of Peptid Backbone 13-15. a. acetic anhydride
b. 0.5 % TFA
c. LDSC; d. Amino functionalized QDs




Figure 13. Synthesis of Peptides 16-18. a. Weak Acid
b. Pyrazole-1-carboxamidine, heat 24 h
c. N6-(2-chloroethyl)guanine




Figure 14. Synthesis of Peptides 19-21 a. Weak acid
b. Pyrazole-1-carboxamidine, heat 24 h
c. i.DIC, II. Amine functionalized QDs




Figure 27. Chemical structures of compounds 27a, 27b, and 27c.




Figure 28. Fluorescence microscopy images of MCF-7 cells treated with 0.05 μ M of 27a for 48 minutes. (A) Phase contrast image of cells treated with 0.05 μ M of 27a for 48 minutes. (B) Fluorescence image of the same field. (C) Merged image of (A) and (B). The scale bar in (B) corresponds to 10 μ m.




Figure 16. Uptake of Quantum Dots Alone in Peripheral MDCK Epithelial Cells - MDCK cells treated with 0.05 mM QDs and incubated at 37°C with 5% CO₂ in humidified air for 90 minutes. **Image (A):** Phase contrast image **Image (B):** Fluorescent image **Image (C):** Merged image of (A) and (B) The scale bar (1 cm) corresponds to 17.5 mm seen by the 100x objective




Figure 17. Uptake of Quantum Dots + Polylysine in Interior MDCK Epithelial Cells - MDCK cells treated with 0.05 mM QDs and incubated at 37°C with 5% CO₂ in humidified air for 90 minutes. Image (A): Phase contrast image Image (B): Fluorescent image Image (C): Merged image of (A) and (B) The scale bar (1 μ m) corresponds to 17.5 μ m seen by the 100x objective




Figure 10. Uptake of Quantum Dot-Polymer conjugates in MCF-7 cells treated with 0.05 μ M QDs and incubated at 37°C with 5% CO₂ in humidified air for 48 hours.
 Image (A): Phase contrast image image;
 (B): Fluorescence image image (C): Merged image of (A) and (B). The same field is imaged consecutively in 1000 nm steps to take the structure.